ZURICH Oct 5 The Swiss blue-chip SMI
was seen opening 0.3 percent down at 8,208 points on Wednesday,
according to premarket indications by bank Julius Baer
The following are some of the main factors expected to
affect Swiss stocks.
The U.S. Food and Drug Administration has granted Roche
breakthrough status to its anti-rheumatoid arthritis medication
Actemra/RoActemra (tocilizumab) for giant cell arteritis (GCA).
Giant cell arteritis is a chronic, potentially life-threatening
autoimmune condition caused by inflammation of large and
medium-sized arteries, most often in the head, but also in the
aorta and its branches.
For more click on
* Daetwyler said on Tuesday it is investing more
than 100 million Swiss francs ($102.04 million) in a new U.S.
plant in Delaware manufacture elastomer components for
injectable drug delivery systems.
($1 = 0.9800 Swiss francs)
(Reporting by Zurich newsroom)